Biomarker for diagnosing obsessive-compulsive disorder and use thereof
The MDM2 gene is utilized as a biomarker for OCD diagnosis, addressing the lack of reliable tools by measuring its expression or activity, enabling accurate OCD diagnosis and prognosis.
Patent Information
- Application Number
- PCT/KR2026/096561
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
There is a lack of objective and reliable diagnostic tools for obsessive-compulsive disorder (OCD), which significantly disrupts daily life and requires a more precise and effective method for diagnosis.
The use of the MDM2 gene as a biomarker for OCD, involving the measurement of its expression or activity level in sample-derived cells, and comparison with a normal control, through a diagnostic kit and method that includes primers, probes, antibodies, and other specific binding agents to identify OCD.
Provides a simple and effective means to diagnose OCD by measuring the MDM2 gene's expression or activity level, offering insights into disease presence, severity, prognosis, and treatment response.
Smart Images

Figure KR2026096561_12112026_PF_FP_ABST
Abstract
Description
Biomarkers for Diagnosing Obsessive-Compulsive Disorder and Their Uses
[0001] The present invention relates to a biomarker for diagnosing obsessive-compulsive disorder and its use.
[0002] Obsessive-Compulsive Disorder (OCD) is a mental disorder characterized by unwanted, recurring thoughts or impulses (obsessions) and repetitive behaviors (compulsions) performed to resolve them. Obsessions are unpleasant or anxiety-inducing thoughts or impulses that arise repeatedly regardless of one's will (Korean Registered Patent No. 10-2397333). Sometimes, unwanted aggressive or immoral thoughts appear repeatedly, leading to severe guilt and anxiety. Compulsive behaviors are actions performed to relieve or prevent the anxiety caused by these obsessions. These typically take the form of repetitive and ritualistic actions; although they may appear irrational to the individual, they are difficult to stop. Typical examples include washing hands or showering dozens of times to avoid contamination, or checking dozens of times whether the door is locked before leaving the house. In addition, it is common to see behaviors such as fixating on specific numbers or sequences of actions to move accordingly, or arranging objects in a fixed position and order.
[0003] Such obsessive-compulsive disorder follows a chronic course and can cause severe disruption to daily life, yet there is still a lack of objective and reliable diagnostic tools.
[0004] One objective of the present invention is to provide a biomarker composition for diagnosing obsessive-compulsive disorder comprising the MDM2 (Mouse double minute 2 homolog) gene.
[0005] Another objective of the present invention is to provide a composition for diagnosing obsessive-compulsive disorder comprising a preparation for measuring the expression or activity level of the MDM2 gene.
[0006] Another objective of the present invention is to provide a kit for diagnosing obsessive-compulsive disorder comprising the above-mentioned composition for diagnosing obsessive-compulsive disorder.
[0007] Another objective of the present invention is to provide a method for providing information for the diagnosis of obsessive-compulsive disorder, comprising the steps of: measuring the expression or activity level of the MDM2 gene in sample-derived cells isolated from an individual; and comparing said expression or activity level with the expression or activity level of a normal control.
[0008] Another objective of this institution is to provide the use of the MDM2 gene as a biomarker for the diagnosis of obsessive-compulsive disorder.
[0009] Another objective of the present invention is to provide a diagnostic use of a preparation or a composition containing the same for measuring the expression or activity level of the MDM2 gene for obsessive-compulsive disorder.
[0010] Another aspect of the present invention is to provide a use of a preparation or a composition containing the same for measuring the expression or activity level of the MDM2 gene for the preparation of a composition for diagnosing obsessive-compulsive disorder.
[0011] One aspect of the present invention is a biomarker composition for diagnosing obsessive-compulsive disorder comprising the MDM2 (Mouse double minute 2 homolog) gene.
[0012] Another aspect of the present invention is a composition for diagnosing obsessive-compulsive disorder comprising a preparation for measuring the expression or activity level of the MDM2 gene.
[0013] The above MDM2 (Mouse Double Minute 2 homolog) gene encodes the MDM2 protein, which is an E3 ubiquitin-protein ligase involved in the process of protein degradation within cells. The MDM2 protein is known to act as a negative regulatory protein that degrades p53 using p53 as a substrate protein and inhibits the activity of p53.
[0014] The term "diagnosis" above refers to confirming the existence or characteristics of a pathological state and may refer to determining an object's susceptibility to a specific disease or condition, determining whether an object possesses a specific disease or condition, determining the prognosis of an object with a specific disease or condition, or monitoring such prognosis. Here, "prognosis" refers to determining the treatment response, improvement or worsening of symptoms, likelihood of relapse, drug responsiveness, development of tolerance, or long-term clinical course in the subject after treatment. This may include, for example, predictions regarding changes in the severity of obsessive-compulsive symptoms, the likelihood of relapse after treatment, and the stability of symptom control, and includes both positive prognoses (e.g., significant reduction in symptoms or long-term stabilization) and negative prognoses (e.g., treatment resistance, frequent relapses, chronic course). For the purposes of the present invention, "diagnosis" may be used as a concept encompassing determining the presence of obsessive-compulsive disorder, evaluating the severity of symptoms, predicting the prognosis, or monitoring the progression of the disease.
[0015] The above terms “marker” or “biomarker” refer to substances capable of distinguishing and evaluating individuals with and without disease, and may include organic biomolecules such as polypeptides, proteins, nucleic acids (e.g., mRNA, etc.), lipids, glycolipids, glycoproteins, sugars (monosaccharides, disaccharides, oligosaccharides, etc.), metabolites, etc., which show an increase or decrease in individuals with disease compared to individuals without disease.
[0016] The present invention may provide a composition comprising a preparation capable of measuring the degree of expression or activity of the aforementioned biomarker, which changes according to the onset of the disease, and / or the degree of expression or activity of the aforementioned biomarker. That is, in this specification, the expression or activity of the gene may refer to the level of mRNA expression or activity of the gene or the level of expression or activity of the protein, and measuring the level of expression or activity of the gene may mean measuring the degree of expression or activity of the aforementioned biomarker, which changes according to the onset of the disease. For example, it may mean measuring the degree of expression or activity of the marker protein with a preparation capable of measuring protein levels, and it may mean measuring the degree of expression or activity of the marker gene with a preparation capable of measuring gene levels.
[0017] In one embodiment, the MDM2 gene may include one or more intracellular MDM2 genes selected from the group consisting of microglia-like cells and microglia.
[0018] The aforementioned microglia are major immune cells of the central nervous system that maintain homeostasis by removing damaged cells, cellular debris, and foreign substances within brain tissue through phagocytosis.
[0019] The aforementioned induced microglia-like cells (iMGs) are cells similar to microglia that are differentiated by treating stem cells, such as iPSCs and ESCs, or monocytes, such as PBMCs, with growth factors. Microglia-like cells can perform immune functions similar to actual microglia, such as phagocytosis, regulation of inflammatory responses, and / or removal of damaged cells.
[0020] In one embodiment, compared to PBMC, the microglia-like cells may have increased expression of one or more of P2RY12, OLFML3, TGFBR1, TMEM119, CSF1R, HEXB, and GPR34, but are not limited thereto.
[0021] In one embodiment, the microglia-like cells may be prepared by treating monocytes differentiated from stem cells or monocytes contained in PBMCs with one or more of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and recombinant human interleukin-34 (IL-34), but are not limited thereto.
[0022] In one embodiment, the preparation may include one or more selected from the group consisting of a primer, a probe, a PNA (peptide nucleic acid), and an antisense nucleotide that specifically binds to the MDM2 gene.
[0023] The above primer is a fragment that recognizes a target gene sequence and may include a pair of forward and reverse primers; preferably, it may be a primer pair that provides analysis results having specificity and sensitivity. High specificity may be conferred when the nucleic acid sequence of the primer is a sequence that is inconsistent with the non-target sequence present in the sample, thereby amplifying only the target gene sequence containing the complementary primer binding site and not causing non-specific amplification.
[0024] The above probe refers to a nucleic acid fragment, such as RNA or DNA, capable of specifically binding to a target nucleic acid, for example, mRNA, and may be labeled to confirm the presence, content, and expression level of a specific mRNA. The probe may be manufactured in the form of an oligonucleotide probe, a single-strand DNA probe, a double-strand DNA probe, an RNA probe, etc. The selection of an appropriate probe and hybridization conditions may be appropriately selected according to techniques known in the relevant art field.
[0025] The above primer or probe can be chemically synthesized using the phosphoramidite solid support method or other widely known methods. These nucleic acid sequences can also be modified using many means known in the art. Non-limiting examples of such modifications include methylation, capping, substitution with one or more homologues of the natural nucleotide, and modification between nucleotides, for example, modification to uncharged linkages (e.g., methyl phosphonate, phosphotriester, phosphoroamidate, carbamate, etc.) or charged linkages (e.g., phosphorothioate, phosphorodithioate, etc.).
[0026] Suitable conditions for hybridizing a probe with a cDNA molecule can be determined through a series of processes via optimization procedures. Such procedures are carried out by those skilled in the art to establish protocols for laboratory use. For example, conditions such as temperature, component concentration, hybridization and washing times, buffer components, and their pH and ionic strength depend on various factors such as probe length, GC amount, and target nucleotide sequence. Detailed conditions for hybridization can be found in Joseph Sambrook, et al., *Molecular Cloning*, *A Laboratory Manual*, *Cold Spring Harbor Laboratory Press*, *Cold Spring Harbor*, NY (2001); and MLM Anderson, *Nucleic Acid Hybridization*, *Springer-Verlag New York Inc.*, NY (1999). For example, among the above strict conditions, high strictness means hybridizing at 65°C in 0.5 M NaHPO4, 7% SDS (sodium dodecylsulfate), and 1 mM EDTA, and washing at 68°C in 0.1 x SSC (standard saline citrate) / 0.1% SDS. Or, high strictness means washing at 48°C in 6 x SSC / 0.05% sodium pyrophosphate. Low strictness means, for example, washing at 42°C in 0.2 x SSC / 0.1% SDS.
[0027] The above PNA refers to peptide nucleic acid (PNA), which refers to a polymer similar to artificially synthesized DNA or RNA. It is a DNA-like structure in which nucleic acid bases are linked by peptide bonds rather than phosphate bonds. While DNA has a phosphate-ribose sugar backbone, PNA has a repeating N-(2-aminoethyl)-glycine backbone linked by peptide bonds, which can significantly increase the binding affinity and stability to DNA or RNA of a target sequence.
[0028] The above antisense nucleotide refers to an oligonucleotide comprising a nucleotide base sequence and a backbone such as a phosphodiester, which can specifically bind to a target RNA sequence through Watson-Crick base pairing and hybridize with the corresponding RNA sequence to form a heteroduplex.
[0029] Primers, probes, PNAs, and antisense nucleotides that specifically bind to the MDM2 gene sequence known in the art can be prepared according to conventional methods in the art.
[0030] In one embodiment, the preparation may comprise one or more selected from the group consisting of antibodies, antibody fragments, interacting proteins, oligopeptides, ligands, nanoparticles, aptamers, avidity multimers, and peptidomimetics that specifically bind to the protein of the MDM2 gene or a peptide fragment thereof.
[0031] The above protein may include not only the protein itself, but also protein isoforms or protein variants that may be generated by splicing and variable promoters, or generated due to genetic changes such as mutations or polymorphisms.
[0032] The above antibody may refer to a substance that specifically binds to the above protein and causes an antigen-antibody reaction. The above antibody may include a polyclonal antibody, a monoclonal antibody, or a recombinant antibody. The above antibody can be easily manufactured using techniques widely known in the art. The above antibody may be separated and purified using methods such as gel electrophoresis, dialysis, salt precipitation, ion exchange chromatography, and affinity chromatography. In addition, the above antibody may include not only a complete form having two full-length light chains and two full-length heavy chains, but also functional fragments of the antibody molecule.
[0033] The above-mentioned interacting protein refers to a protein having a protein-protein interaction (PPI) with the above-mentioned protein, and may refer to a protein having a highly specific physical contact as a result of biochemical actions regulated by interactions including electrostatic force, hydrogen bonding, and hydrophobic effects.
[0034] The above oligopeptide is composed of 2 to 20 amino acids as a peptide and may include dipeptides, tripeptides, tetrapeptides, and pentapeptides, but is not limited thereto.
[0035] The above aptamer refers to a single-stranded oligonucleotide and may refer to a nucleic acid molecule having binding activity to the protein. The above aptamer may have various secondary or tertiary structures depending on its base sequence and may have high affinity for a specific substance, such as in an antigen-antibody reaction. The above aptamer may be RNA, DNA, modified nucleic acid, or a mixture thereof, and may be linear or cyclic in form.
[0036] Since information regarding the protein or the gene encoding it, which is a marker according to the present invention, is known in the art, a person skilled in the art can design a preparation for measuring the level of said protein or the gene encoding it based thereon.
[0037]
[0038] Another aspect of the present invention is a kit for diagnosing obsessive-compulsive disorder comprising the above-mentioned composition for diagnosing obsessive-compulsive disorder.
[0039] In one embodiment, the kit may be an ELISA kit, a protein chip kit, a rapid kit, an MRM (Multiple reaction monitoring) kit, an RT-PCR kit, or a DNA chip kit. However, it is not limited thereto.
[0040] The above kit may further include one or more other component compositions, solutions, or devices suitable for the analysis method.
[0041] The above ELISA kit may include essential elements necessary for performing ELISA. The ELISA kit may include an antibody specific to the protein. The antibody is an antibody with high specificity and affinity for the marker protein and little cross-reactivity to other proteins, and is a monoclonal antibody, a polyclonal antibody, or a recombinant antibody. Additionally, the above ELISA kit may include an antibody specific to a control protein (e.g., a housekeeping protein). Furthermore, the ELISA kit may include reagents capable of detecting the bound antibody, such as a labeled secondary antibody, chromophores, an enzyme (e.g., conjugated with the antibody) and its substrate, or other substances capable of binding to the antibody.
[0042] The protein chip kit described above may include essential elements necessary for performing protein chip operations. The protein chip kit may include a substrate to which a protein or a fragment thereof is attached, and reagents, formulations, enzymes, etc., for producing fluorescently labeled probes. Additionally, the substrate may include a control protein or a fragment thereof, but is not limited thereto.
[0043] The above rapid kit may consist of a sample pad to which a sample is applied, a membrane on which an antibody is immobilized, and an absorbent pad capable of absorbing the sample, but is not limited thereto.
[0044] The above MRM kit may further include essential elements necessary to perform multiple reaction monitoring. The MRM kit may include a peptide that selectively recognizes the protein.
[0045] The above RT-PCR kit may further include essential components necessary to perform a reverse transcription polymerase chain reaction. The reverse transcription polymerase chain reaction kit may include a primer pair specific to the gene. The primer is a nucleotide having a sequence specific to the nucleic acid sequence of the gene and may have a length of about 7 bp to 50 bp, more preferably about 10 bp to 30 bp. It may also include a primer specific to the nucleic acid sequence of a control gene (e.g., a housekeeping gene). In addition, the reverse transcription polymerase chain reaction kit may include, but is not limited to, a test tube or other suitable container, a reaction buffer (with varying pH and magnesium concentration), deoxynucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase, RNase inhibitor DEPC-water, sterile water, etc.
[0046] The above DNA chip kit may include essential elements necessary for performing DNA chip operations. The DNA chip kit may include a substrate to which cDNA or oligonucleotides corresponding to a gene or a fragment thereof are attached, and reagents, preparations, enzymes, etc., for producing fluorescently labeled probes. Additionally, the substrate may include cDNA or oligonucleotides corresponding to a control gene (e.g., a housekeeping gene) or a fragment thereof, but is not limited thereto.
[0047] In addition, the above kit may be an integrated magneto-electrochemical sensor kit. An integrated magneto-electrochemical sensor refers to a system that detects an electrical signal by enzymatic signal amplification using magnetic beads. Specifically, it may refer to a system that attaches a substance capable of detecting a target substance (e.g., an antibody) to magnetic beads and detects an electrical signal by enzymatic signal amplification generated by a chromogenic substance capable of detecting the target substance (e.g., horseradish peroxidase (HRP), alkaline phosphatase (ALP), α-D-galactosidase (α-Gal).
[0048] In one embodiment, the kit may include a computer with a built-in formulation, device, and algorithm for measuring the level of mRNA of the protein or the gene encoding it, and may relate the result of measuring the level of the marker to the prediction of obsessive-compulsive disorder through the algorithm.
[0049]
[0050] Another aspect of the present invention is a method for providing information for the diagnosis of obsessive-compulsive disorder, comprising the steps of: measuring the expression or activity level of an MDM2 gene in sample-derived cells isolated from an individual; and comparing said expression or activity level with the expression or activity level of a normal control.
[0051] The above-mentioned entity refers to a biological being that is the subject of the present invention and may be selected from a group consisting of various animal species such as mammals, birds, reptiles, amphibians, and fish, and preferably may be a human, but is not limited thereto.
[0052] The above normal control group may refer to individuals who have not developed obsessive-compulsive disorder, individuals who have not developed obsessive-compulsive disorder and social anxiety disorder, or normal individuals who are not suffering from any disease.
[0053] The above-mentioned sample means obtained from a patient at risk of obsessive-compulsive disorder, a patient who has developed obsessive-compulsive disorder, or an individual suspected of developing obsessive-compulsive disorder; or any substance, biological fluid, tissue, or cell derived from these.
[0054] In one embodiment, the sample may be blood, spleen, or a combination thereof.
[0055] In order to measure the level of a marker protein or mRNA of a gene encoding it within a sample isolated from a subject, the method of the present invention may perform appropriate treatment (e.g., removal of abundant protein, peptide formation, etc.) on the sample according to methods known in the art.
[0056] In one embodiment, the step of measuring the expression or activity level may include: culturing peripheral blood monocytes derived from a sample isolated from an individual to differentiate them into microglia-like cells; and measuring the expression or activity level of the MDM2 gene in the microglia-like cells.
[0057] In one embodiment, the step of measuring the expression or activity level may further include the step of isolating peripheral blood monocytes from a sample isolated from an individual.
[0058] In one embodiment, the method of the present invention may further include the step of determining that the individual has obsessive-compulsive disorder if the expression or activity level of the MDM2 gene is reduced compared to a normal control group.
[0059] In one embodiment, the step of measuring the expression level may include the step of measuring the mRNA level of the MDM2 gene.
[0060] In one embodiment, the measurement of the mRNA level may be performed by a method selected from the group consisting of polymerase chain reaction (PCR), real-time polymerase chain reaction (qPCR), reverse transcription polymerase chain reaction (RT-PCR), competitive polymerase chain reaction (competitive RT-PCR), nuclease protection assay (RNase and S1 nuclease protection assay), in situ hybridization, nucleic acid microarray, northern blotting, or DNA chip, but is not limited thereto.
[0061] In one embodiment, the step of measuring the expression level may include the step of measuring the protein level of the MDM2 gene.
[0062] In one embodiment, the measurement of the protein level may be performed by a method selected from the group consisting of protein mass spectrometry, protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Desorption / Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Surface Enhanced Laser Desorption / Ionization Time of Flight Mass Spectrometry) analysis, radioimmunoassay, radioimmunodiffusion, Ouchteroni immunodiffusion, Rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis, liquid chromatography-mass spectrometry (LC-MS), LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry), Western blot, and ELISA (Enzyme Linked Immunosorbent Assay), but is not limited thereto.
[0063] Another aspect of this study is the use of MDM2 as a biomarker for the diagnosis of obsessive-compulsive disorder.
[0064] Another aspect of the present invention is the use of a preparation or a composition containing the same for measuring the expression or activity level of the MDM2 gene for the diagnosis of obsessive-compulsive disorder.
[0065] Another aspect of the present invention is the use of a preparation or a composition containing the same for measuring the expression or activity level of the MDM2 gene for the preparation of a composition for diagnosing obsessive-compulsive disorder.
[0066] A composition for diagnosing obsessive-compulsive disorder according to one aspect, or a method for providing information for the diagnosis thereof, utilizes the disease-specific MDM2 gene as a biomarker, and can diagnose obsessive-compulsive disorder simply and effectively by measuring the expression or activity level of said gene.
[0067] Figure 1 is a figure showing the process of differentiation of peripheral blood monocytes (PBMCs) obtained from the blood of a normal control group (HC), patients with obsessive-compulsive disorder (OCD), and patients with social anxiety disorder (SAD) into microglia-like cells (iMG).
[0068] Figure 2 is a graph showing the expression levels of P2RY12, OLFML3, and TGFBR1 in iMG of HC (HC-iMG), iMG of OCD (OCD-iMG), and iMG of SAD (SAD-iMG) as relative quantity levels (Relative Quantity value; RQ value) compared to PBMCs.
[0069] Figure 3 is a confocal microscope view of HC-iMG (HC-MLCs), OCD-iMG (OCD-MLCs), and SAD-iMG (SAD-MLCs) stained by immunohistochemical staining.
[0070] Figure 4a shows images of HC-iMG, OCD-iMG, and SAD-iMG that have ingested latex beads, observed using a confocal microscope.
[0071] Figure 4b is a graph showing a comparative analysis of the number of beads phagocytosed per cell by HC-iMG, OCD-iMG, and SAD-iMG that phagocytosed latex beads.
[0072] Figure 5a shows images of HC-iMG, OCD-iMG, and SAD-iMG that have phagocytosed pHrodo-zimosan particles, observed using a confocal microscope.
[0073] Figure 5b is a graph comparing the number of particles phagocytosed per cell by HC-iMG, OCD-iMG, and SAD-iMG that phagocytosed pHrodo-zimosan particles.
[0074] Figure 6 is a graph comparing the normalized counts of MDM2, NME1, ZMAT3, and SHISA5 expressed in HC-iMG and OCD-iMG.
[0075] Figures 7a to 7d show graphs verifying the gene expression levels of MDM2, NME1, ZMAT3, and SHISA5 in iMG relative to PBMC in HC, OCD, and SAD using qPCR. In each graph, the left side of the center dotted line represents the measured gene expression levels of PBMC, and the right side represents the measured gene expression levels of iMG.
[0076] Figure 8a shows an image of iMG MDM2 expression observed in HC, OCD, and SAD using immunohistochemical staining.
[0077] Figure 8b is a graph showing the comparative analysis of MDM2 expression levels in HC, OCD, and SAD measured by fluorescence intensity.
[0078] Figure 9 is a graph showing the correlation between the expression of the Dimensional Obsession Scale, specifically the subscale related to germophobia (DIM01) and MDM2.
[0079]
[0080] The present invention will be explained in more detail below through examples. However, these examples are intended to illustrate the invention and the scope of the invention is not limited to these examples.
[0081] Each description and embodiment disclosed herein may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the invention. Furthermore, the scope of the invention is not to be limited by the specific descriptions provided below.
[0082]
[0083] The study conducted in the examples was reviewed and approved by the Institutional Review Boards of Yonsei University Severance Hospital (Severance Hospital IRB No. 4-2022-1586) and Gangnam Severance Hospital (Gangnam Severance Hospital IRB No. 3-2021-0267) in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.
[0084]
[0085] Reference Example. Statistical Analysis
[0086] The experimental results of the following examples were statistically analyzed, and to explain the statistics more accurately, statistical outliers were identified and normality tests were performed. Statistical outliers were removed using the ROUT test (Q < 0.5%). The cleaned datasets were tested for normality using the Kolmogorov-Smirnov and Shapiro-Wilk tests. The statistical significance of differences between groups was evaluated using a paired t-test to compare signature genes between PBMCs and microglia-like cells. Statistically significant differences are indicated as follows:
[0087] **** (p < 0.0001), *** (p < 0.001), ** (p < 0.01) and, * (p < 0.05).
[0088]
[0089] Examples
[0090] Example 1. Preparation of induced microglia-like cells (iMG)
[0091] 1-1. Participant Selection
[0092] Patients were recruited from the Department of Psychiatry at Yonsei University Severance Hospital from March 2023 to August 2024 and from the Department of Psychiatry at Gangnam Severance Hospital from March 2023 to April 2024. Individual interviews with psychiatrists confirmed the absence of a personal or first-degree relative history of mental illness. All participants were of Korean descent. Ultimately, 19 patients with obsessive-compulsive disorder, 16 patients with social anxiety disorder, and 20 control subjects were included in this study. The status, characteristics, and symptom severity of patients with social anxiety disorder and obsessive-compulsive disorder were measured at baseline.
[0093] State symptoms include the Brief Fear of Negative Evaluation Scale (BFNE), Generalized Anxiey Disorder-7 (GAD-7), Hospital Anxiety and Depression Scale (HADS), Liebowitz Social Anxiety Scale (LSAS), Maudsley Obesesive-Compulsive Inventory (MOCI), Panic Disorder Severity Scale (SWLS), and FCV-19 Fear of COVID-19 Scale (FCV-19S). Penn State Worry Questionnaire (PSWQ), State-Trait Anxiety Inventory (STAI-X-1), State-Trait Anxiety Inventory-Trait (STAI-X-2), Dimensional Obsessive-Compulsive Scale (DIM01), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Yale-Brown Obsessive Compulsive Scale (YBOCS), Using the Obsessive-Compulsive Inventory (OCI) evaluated.
[0094] Specific state symptoms in patients with obsessive-compulsive disorder were evaluated using MADRS (Montgomery-Asberg Depression Rating Scale), OCI-RK (obsessive-compulsive inventory-revised-Korean), BDI (Beck depression inventory), BAI (Beck anxiety inventory), YBOCS (Yale-Brown Obsessive-Compulsive Scale), DOCS (dimensional obsessive-compulsive scale, DIM01 (subscale 1 of DOCS (contamination)).
[0095] The selection and exclusion criteria for subjects with obsessive-compulsive disorder and social anxiety disorder are as follows.
[0096] 1) Selection Criteria for Subjects with Obsessive-Compulsive Disorder
[0097] ① Ages 19–75
[0098] ② Cases diagnosed with obsessive-compulsive disorder based on DSM-IV or DSM-5
[0099] ③ If the diagnostic criteria for major depressive disorder are met, the diagnostic criteria for obsessive-compulsive disorder were satisfied prior to the diagnosis of major depressive disorder, and the patient's primary complaint is obsessive-compulsive disorder.
[0100] ④ Cases where the purpose and process of the research have been fully understood and agreed to
[0101]
[0102] 2) Exclusion criteria for subjects with obsessive-compulsive disorder
[0103] ① Cases accompanied by chronic movement disorders or chorea
[0104] ② Cases where the patient has a psychotic disorder such as schizophrenia
[0105] ③ Cases where there is a history or current history of body dysmorphic disorder that is difficult to differentiate from obsessive-compulsive disorder
[0106] ④ If there is evidence of alcohol or other substance dependence within the past 6 months
[0107] ⑤ In cases of a history of brain surgery, encephalitis, or brain injury
[0108] ⑥ When the diagnostic criteria for major depression are met prior to meeting the diagnostic criteria for obsessive-compulsive disorder, or when the patient's chief complaint is depressive symptoms
[0109] ⑦ Cases where the contents of the consent form are not read and understood
[0110]
[0111] 1) Selection Criteria for Social Anxiety Disorder Subjects
[0112] ① Ages 19–75
[0113] ② In cases where social anxiety disorder is diagnosed based on DSM-IV or DSM-5
[0114] ③ If the diagnostic criteria for major depressive disorder are met, the diagnostic criteria for social anxiety disorder were satisfied prior to the diagnosis of major depressive disorder, and the patient's primary complaint is social anxiety disorder.
[0115] ④ Cases where the purpose and process of the research have been fully understood and agreed to
[0116] 2) Exclusion criteria for subjects with social anxiety disorder
[0117] ① Cases accompanied by chronic movement disorders or chorea
[0118] ② Cases where the patient has a psychotic disorder such as schizophrenia
[0119] ③ Cases where there is a history or current history of body dysmorphic disorder that is difficult to differentiate from social anxiety disorder
[0120] ④ If there is evidence of alcohol or other substance dependence within the past 6 months
[0121] ⑤ In cases of a history of brain surgery, encephalitis, or brain injury
[0122] ⑥ When the diagnostic criteria for major depression are met prior to meeting the diagnostic criteria for social anxiety disorder, or when the patient's chief complaint is depressive symptoms
[0123] ⑦ Cases where the contents of the consent form are not read and understood
[0124]
[0125] Ultimately, 17 patients with obsessive-compulsive disorder, 12 patients with social anxiety disorder, and 16 normal control subjects were included in this study.
[0126]
[0127] 1-2. Establishment of Microglia-like Cells
[0128] Peripheral blood mononuclear cells obtained from the blood of patients with obsessive-compulsive disorders (OCD), patients with social anxiety disorder (SAD), and healthy controls (HC) were cultured for 14 days in a medium supplemented with interleukin 34 and granulocyte-macrophage colony stimulating factor to differentiate them into microglia-like cells.
[0129] Specifically, after obtaining peripheral blood (~30 mL) from a normal control group, patients with obsessive-compulsive disorder, and patients with social anxiety disorder using heparin-treated tubes, Density Gradient Media (Lymphoprep TMPeripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using STEMCELL technologies (Catalog# 07851 / 07861) and resuspended in Roswell Park Memorial Institute (RPMI) 1640 buffer (Gibco, Waltham, MA, USA) containing 10% Fetal Bovine Serum (FBS; Gibco) and 1% Penicillin / Streptomycin (Gibco). The isolated PBMCs were incubated overnight at 37°C in a 5% CO2 incubator for 5 x 10 minutes. 5 The cells were seeded at a density of cells / ml. The remaining PBMCs were used for qPCR analysis. The medium was carefully aspirated, and adherent cells were cultured for 14 days in RPMI 1640 buffer (Gibco, Waltham, MA, USA) containing 1% P / S, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (10 ng / ml; R&D Systems, Minneapolis, MN, 215-GM), and recombinant human interleukin-34 (IL-34) (100 ng / ml; R&D Systems, Minneapolis, MN, 5265-IL) to establish microglia-like cells.
[0130] After culturing for 14 days and observing with an optical microscope on the 14th day, it was confirmed that several peripheral blood mononuclear cells obtained from the blood of patients with obsessive-compulsive disorder and related disorders, patients with social anxiety disorder, and a normal control group had differentiated (Fig. 1).
[0131]
[0132] Example 2. Confirmation of differentiation of microglia-like cells via qPCR
[0133] The expression levels of P2RY12, OLFML3, and TGFBR1, known as representative signature transcripts of microglia, were analyzed using quantitative polymerase chain reaction (qPCR) in microglia-like cells of patients with obsessive-compulsive disorder, patients with social anxiety disorder, and normal control groups to verify whether differentiation into microglia-like cells had occurred well.
[0134] Specifically, qPCR was performed by extracting total RNA using the TRIzol reagent (Invitrogen, Waltham, MA, USA, 15596018) and evaluating it using a NanoDrop spectrometer (DeNovix, Wilmington, DE, USA, DS-11FX).
[0135] cDNA was synthesized using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific™, Waltham, MA, USA, K1622).
[0136] To evaluate microglia characteristics in PBMCs and microglia-like cells, the expression of P2RY12 (QIAGEN, hilden, Germany, PPH02545B), OLFML3 (QIAGEN, PPH07681A), and TGFBR1 (QIAGEN, PPH00237C) was analyzed.
[0137] cDNA was amplified with primers using Applied QuantStudio Design & Analysis Software v1.5.1 and Power SYBR Green PCR Master Mix (Applied Biosystems, Waltham, USA, 4367659) at 95°C for 10 minutes, followed by 50 cycles of 15 seconds at 95°C and 1 minute at 60°C. A melting curve was generated to examine the specificity of the amplification. The relative quantity value (RQ value) was calculated using the 2-△△ Ct method with glyceraldehyde 3-phosphate dehydrogenase as a standard internal control.
[0138] As a result, the expression of P2RY12, OLFML3, and TGFBR1 transcripts was statistically significantly increased in microglia-like cells of both the patient group and the control group compared to each PBMC, confirming that differentiation into microglia-like cells was successfully achieved in both the patient group and the control group (Fig. 2).
[0139]
[0140] Example 3. Confirmation of mature microglia protein expression via immunohistochemical staining
[0141] Immunohistochemical staining was used to verify whether TMEM119, P2RY12, and IBA1 proteins, which are specifically expressed on the cell surface of microglia, are expressed in microglia-like cells of patients with obsessive-compulsive disorder, patients with social anxiety disorder, and normal control groups.
[0142] Specifically, microglia-like cells from patients with obsessive-compulsive disorder, patients with social anxiety disorder, and normal controls were fixed with 4% paraformaldehyde and permeated with 0.5% Triton X-100 for 10 minutes. Indirect immunofluorescence was performed using the following primary antibodies:
[0143] anti-IBA1 (Wako, Osaka, Japan, 019-19741; 1:500), anti-P2Y12 (Abcam, Cambridge, UK, ab140862; 1:500), anti-TMEM119 (Novus Biologicals, CO, USA, NBP2-30551; 1:500), anti-MDM2 (Cell Signaling Technology, MA, USA, 86934, 1:500).
[0144] Cells were incubated overnight at 4°C with a primary antibody diluted with 0.5% Triton X-100 (Thermo Scientific™, Waltham, MA, USA, T8787) in PBS (Welgene, South Korea, LB 004-01). After adding 0.5% Triton X-100 in PBS for 15 minutes and rinsing three times, the Donkey anti-rabbit Alexa 488-conjugated secondary antibody (Invitrogen, Waltham, MA, USA, A-21206, 1:200) or the Donkey anti-rabbit Alexa 647-conjugated secondary antibody (Invitrogen, Waltham, MA, USA, A-31573, 1:200) was used for detection. Microglia-like cells were attached using a ProLong™ Gold Antifade mounting solution containing DAPI (Invitrogen, Waltham, MA, USA, P36931). Fluorescence images were captured using a confocal microscope (TCS SP5 II; Leica Microsystems, Wetzlar, Germany).
[0145] As a result, it was confirmed that TMEM119, known as a marker of mature microglia, was weakly expressed in microglia-like cells of patients with obsessive-compulsive disorder, patients with social anxiety disorder, and normal control groups, while P2RY12 and IBA1 were well expressed (Fig. 3).
[0146] From this, immunohistochemical staining confirmed that cells from patients with obsessive-compulsive disorder, patients with social anxiety, and normal controls successfully differentiated into microglia-like cells.
[0147]
[0148] Example 4. Evaluation of phagocytic activity of microglia-like cells in a normal control group and patients with obsessive-compulsive disorder and social anxiety disorder.
[0149] To evaluate the phagocytosis of microglia-like cells in normal control groups, patients with obsessive-compulsive disorder, and patients with social anxiety disorder, pHrodo-zymosan bioparticles and latex beads attached with pHrodo, a detector that senses the degree of acidification, were used.
[0150] Specifically, to quantify phagocytic latex beads (2 μm; Sigma-Aldrich, St. Louis, MO, USA, L3030) and pHrodo-zimosan particles (Thermo Scientific™, Waltham, MA, USA, P35364) in microglia-like cells, microglia-like cells optimally cultured for 14 days were treated with 2 μl of red fluorescent latex beads and pHrodo-zimosan particles at 37°C for 2 hours. Then, phagocytosis was stopped by adding 2 ml of cold PBS. The cells were washed twice with cold PBS, fixed, and stained with microglia markers counterstained with DAPI. The cells were analyzed using a confocal microscope.
[0151] As a result, it was confirmed that the number of latex beads (Figs. 4a, 4b) and pHrodo-zimosan particles (Figs. 5a, 5b) in microglia-like cells of patients with obsessive-compulsive disorder and social anxiety disorder was reduced compared to the normal control group.
[0152] From this, it was confirmed that the phagocytic activity of patients with obsessive-compulsive disorder and social anxiety disorder was reduced compared to the normal control group.
[0153]
[0154] Example 5. Transcriptome analysis of microglia-like cells in a normal control group, patients with obsessive-compulsive disorder, and patients with social anxiety disorder.
[0155] Microglia-like cells of 13 normal control subjects, 14 patients with obsessive-compulsive disorder, and 11 patients with social anxiety disorder were analyzed using RNA sequencing, and genes showing significant differences in expression were identified through gene set enrichment analysis. Additionally, 9 gene sets showing the greatest changes in annotation compared to previously known gene sets were plotted as shown in Table 1 below. The gene set enrichment analysis followed the analysis method of the paper *Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles* (A Subramanian, P Tamayo, VK Mootha, S Mukherjee, BL Ebert, MA Gillette Proc, et al. Natl. Acad. Sci. USA, 2005), and the gene set used was the gene set collection database of the paper *Molecular signatures database (MSigDB) 3.0* (A Liberzon, A Subramanian, R Pinchback, H Thorvaldsdottir, P Tamayo, JP Mesirov, et al. Bioinformatics, 2011).
[0156] The gene sets marked in gray are gene sets of similar lineages, such as the cell cycle and p53 pathway, and their expression was decreased in microglia-like cells of patients with obsessive-compulsive disorder compared to normal controls. For the three gene sets with the largest statistical difference (nominal p-value), the top genes belonging to the regions of increased gene expression were summarized (Table 2). The genes marked in gray (MDM2, NME1, ZMAT3, SHISA5) are genes that appeared repeatedly across the four gene sets and were verified in subsequent analyses (Table 2).
[0157] The aforementioned 13 microglia-like cells from normal control groups (HC-iMG), 13 microglia-like cells from patients with obsessive-compulsive disorder (OCD-iMG), and 11 microglia-like cells from patients with social anxiety (SAD-iMG) were selected for RNA sequencing after passing raw readout data quality control, which determines the RNA quantity and purity—the minimum requirements enabling transcriptome analysis. Ribonucleic acid sequencing was performed by referring to a previous study (PMID: 36750547). Gene classification was based on searches performed using DAVID (http: / david.abcc.ncifcrf.gov / ). For gene set enrichment analysis (GSEA), the GSEA program developed by the Broad Institute, which possesses the molecular signature database, was used.
[0158] Rank databaseGene setp-value1KEGGp53 signaling pathway0.00672ReactomeRegulation of RUNX1 expression and activity0.0133Wikipathwayclear cell renal cell carcinoma pathway0.0174KEGGcell cycle0.0225KEGGglucagon signaling pathway0.0236Reactomeoncogene induced senescence0.0457Reactomeregulation of MECP2 expression and activity0.0458ReactomeTranscriptional regulation by NPAS40.0489WikipathwaymiRNA regulation of p53 pathway in prostate cancer0.05
[0159] Pathway Gene Name Pathway Gene Name Pathway Gene Name KEGG:p53 signaling pathway MDM2Reactome:Oncogene induced senescence MDM2WP:p53 pathway MDM2FBXW7NME1ZMAT3NME1PBRM1SHISA5SETD2CALRKMT2AFABP4RPM2BSHISA5ZMAT3CCND3
[0160] Example 6. Comparison of Transcriptome (MDM2, NME1, ZMAT3, SHISA5) Expression in Microglia-like Cells of Normal Control Group and Patients with Obsessive-Compulsive Disorder
[0161] The normalized counts of the MDM2 (QIAGEN, PPH00193E), NME1 (QIAGEN, PPH01314B), ZMAT3 (QIAGEN, PPH02180B), and SHISA5 (QIAGEN, PPH19699A) genes associated with the p53 pathway were compared in the RNA sequencing data of Example 5.
[0162] As a result, it was confirmed that compared to normal control groups, the expression of MDM2 and ZMAT3 genes in patients with obsessive-compulsive disorder decreased, while the expression of NME1 and SHISA5 genes increased (Fig. 6).
[0163]
[0164] Example 7. Comparison of iMG Transcriptome (MDM2, NME1, ZMAT3, SHISA5) Expression in Normal Control Group, Patients with Obsessive-Compulsive Disorder, and Patients with Social Anxiety Disorder via qPCR
[0165] The expression of the MDM2, NME1, ZMAT3, and SHISA5 genes (MDM2 (QIAGEN, PPH00193E), NME1 (QIAGEN, PPH01314B), ZMAT3 (QIAGEN, PPH02180B), SHISA5 (QIAGEN, PPH19699A) was compared in PBMCs and microglia-like cells of normal control groups, patients with obsessive-compulsive disorder, and patients with social anxiety disorder through qPCR.
[0166] Specifically, the qPCR analysis method was the same as that of Example 2 above, but the expression of MDM2, NME1, ZMAT3, and SHISA5 genes was verified.
[0167] As a result, among the aforementioned genes, only MDM2 showed a statistically significant decrease in expression in microglia-like cells of patients with obsessive-compulsive disorder, while it did not show any change in expression in patients with social anxiety disorder. In PBMCs, no difference was observed between groups. Therefore, it was confirmed that MDM2 is directly related to patients with obsessive-compulsive disorder only in microglia-like cells of patients with obsessive-compulsive disorder (Figs. 7a to 7d).
[0168]
[0169] Example 8. Comparative analysis of MDM2 expression in iMGs in normal controls, patients with obsessive-compulsive disorder, and patients with social anxiety disorder via immunohistochemical staining
[0170] The expression of the MDM2 gene was compared between a normal control group, patients with obsessive-compulsive disorder, and patients with social anxiety disorder using immunohistochemical staining. The immunohistochemical staining method was the same as that of Example 3 above, but only the expression of MDM2 was verified.
[0171] As a result, it was confirmed that fluorescence was observed in the microglia-like cells of the normal control group and patients with social anxiety disorder, but almost no fluorescence was observed in the microglia-like cells of patients with obsessive-compulsive disorder. Additionally, it was confirmed that there was a statistically significant decrease in the expression of MDM2 in the microglia-like cells of patients with obsessive-compulsive disorder compared to the normal control group and the social anxiety disorder patient group (Figs. 8a, 8b).
[0172] From this, it was confirmed that a decrease in MDM2 expression is associated with obsessive-compulsive disorder but not with social anxiety disorder.
[0173]
[0174] Example 9. Analysis of the Relationship between the Dimensional Obsession Scale and MDM2 Expression via Spearman Correlation Analysis
[0175] Spearman correlation analysis was used to analyze the correlation between the obsessive-compulsive subscale of the Dimensional Obsessive-Compulsive Scale and MDM2 expression in microglia-like cells. GraphPad Prism version 10 (GraphPad, La Jolla, CA, USA) was used for Spearman correlation analysis.
[0176] As a result, it was confirmed that there is a negative correlation between the subscale related to germophobia and the expression of MDM2, as the expression of MDM2 has an inverse trend line (Fig. 9).
[0177] From this, it was confirmed that as MDM2 expression decreased, the symptoms of obsessive-compulsive disorder became more severe.
[0178]
[0179] Example 10. Comparative analysis of MDM2 mRNA expression levels, phagocytic latex beads, and zymosan particle counts via Spearman correlation analysis
[0180] Spearman correlation analysis was performed on clinical scales of patients with obsessive-compulsive disorder, MDM2 mRNA expression levels in microglia-like cells derived from patients with obsessive-compulsive disorder, and the number of phagocytic latex beads and zymosan particles. GraphPad Prism version 10 (GraphPad, La Jolla, CA, USA) was used for Spearman correlation analysis.
[0181] As a result, it was confirmed that among the clinical scales of patients with obsessive-compulsive disorder, the mRNA expression levels of DIM01 and MDM2 and the number of phagocytosed latex beads had a statistically significant negative correlation, and the number of phagocytosed latex beads had a statistically significant negative correlation with YBOCS (Table 3).
[0182] From this, it was confirmed that a decrease in MDM2 mRNA expression in microglia-like cells is associated with reduced phagocytosis and symptoms of obsessive-compulsive disorder.
[0183] OCDMDM2 Predatory Bead Predatory Zimotic Particle OCIC Correlation Coefficient 0.04569 - 0.2039 - 0.2074 Sig. (two-tailed) 0.8526 0.4025 0.3943 N191919DIM01 Correlation Coefficient - 0.4605 - 0.4728 0.0167 Sig. (two-tailed) 0.0473 * 0.0409 * 0.9459 N191919BDIC Correlation Coefficient - 0.2328 - 0.1843 0.04497 Sig. (two-tailed) 0.3375 0.45 0.8549 N191919BAIC Correlation Coefficient - 0.2054 - 0.4363 - 8815 Sig. (two-tailed)0.3990.06180.9714N191919YBOCSCorrelation Coefficient-0.3017-0.5664-0.2005Sig. (two-tailed)0.20940.0115*0.4104N191919MADRSCorrelation Coefficient-0.07381-0.08084-0.04042Sig. (two-tailed)0.76390.74220.8695N191919
[0184] From the foregoing description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as including all modifications or variations derived from the meaning and scope of the claims set forth below and their equivalents, rather than from the detailed description above.
Claims
A biomarker composition for diagnosing obsessive-compulsive disorder comprising the MDM2 (Mouse double minute 2 homolog) gene. A composition for diagnosing obsessive-compulsive disorder comprising a preparation for measuring the expression or activity level of the MDM2 gene. A composition for diagnosing obsessive-compulsive disorder according to claim 2, wherein the MDM2 gene comprises one or more intracellular MDM2 genes selected from the group consisting of microglia-like cells and microglia. A composition for diagnosing obsessive-compulsive disorder according to claim 2, wherein the preparation comprises one or more selected from the group consisting of a primer, a probe, a PNA (peptide nucleic acid), and an antisense nucleotide that specifically binds to the MDM2 gene. A composition for diagnosing obsessive-compulsive disorder according to claim 2, wherein the formulation comprises one or more selected from the group consisting of an antibody that specifically binds to a protein of the MDM2 gene or a peptide fragment thereof, an antibody fragment, an interacting protein, an oligopeptide, a ligand, nanoparticles, an aptamer, an avidity multimer, and peptidomimetics. A kit for diagnosing obsessive-compulsive disorder comprising the composition of any one of claims 2 to 5. A step of measuring the expression or activity level of the MDM2 gene in sample-derived cells isolated from an individual; and A method for providing information for the diagnosis of obsessive-compulsive disorder, comprising the step of comparing the above expression or activity level with the expression or activity level of a normal control group. In claim 7, the step of measuring the expression or activity level comprises: culturing sample-derived peripheral blood monocytes isolated from an individual to differentiate them into microglia-like cells; and A method comprising the step of measuring the expression or activity level of the MDM2 gene of microglia-like cells. A method according to claim 7, further comprising the step of determining that the individual has obsessive-compulsive disorder when the expression or activity level of the MDM2 gene is reduced compared to a normal control group. In claim 7, the step of measuring the expression or activity level includes the step of measuring the mRNA level of the MDM2 gene, and A method wherein the measurement of mRNA levels is performed by any one or more selected from the group consisting of polymerase chain reaction (PCR), real-time polymerase chain reaction (qPCR), reverse transcription polymerase chain reaction (RT-PCR), competitive polymerase chain reaction (competitive RT-PCR), nuclease protection assay (RNase and S1 nuclease protection assay), in situ hybridization, nucleic acid microarray, northern blotting, and DNA chips. In claim 7, the step of measuring the expression level includes the step of measuring the protein level of the MDM2 gene, and A method wherein the measurement of protein levels is performed by any one or more selected from the group consisting of protein mass spectrometry, protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Desorption / Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Surface Enhanced Laser Desorption / Ionization Time of Flight Mass Spectrometry) analysis, radioimmunoassay, radioimmunodiffusion, Ouchteroni immunodiffusion, Rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis, liquid chromatography-mass spectrometry (LC-MS), LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry), Western blot, and ELISA (Enzyme Linked Immunosorbent Assay). A method according to any one of claims 7 to 11, wherein the sample is the blood or spleen of an individual.
